source
- Astellas teams up with Boston miniprotein startup to explore AI-designed tiny proteinsAstellas Pharma announced a partnership with a Boston-based startup that specializes in miniproteins, small engineered proteins that can serve as therapeutic agents. The startup leverages artifici…
- Lycia Therapeutics targets $228M IPO to fund food allergy protein degrader programsLycia Therapeutics announced plans for an initial public offering expected to raise about $228 million. The proceeds are intended to support its pipeline of protein degrader therapeutics targeting…